Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so conclusive that the company not only halted the study for efficacy ...

Merck recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining by 3.3%.

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...

Merck (MRK) announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR compared to placebo in adults with pulmonary arterial hypertension WHO functional class ...

Merck has an Earnings ESP of -2.04% and a Zacks ... New pulmonary arterial hypertension (PAH) drug Winrevair is likely to have contributed to sales growth with most sales coming from the U.S ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and pulmonary arterial hypertension-related hospitalization by 76%. Results from ...

Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

(RTTNews) - Merck (MRK), known as MSD outside of the United States and Canada, Monday announced the first presentation of results from the Phase 3 Zenith trial evaluating Winrevair (sotatercept ...

WINREVAIR showed a reduction in the composite ... These developments are based on a press release statement from Merck. According to InvestingPro analysis, Merck maintains strong financial health ...

Merck recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining by 3.3%.